BTIG raised the firm’s price target on Natera (NTRA) to $85 from $75 and keeps a Buy rating on the shares after the company won a preliminary injunction order in a patent infringement case against NeoGenomics (NEO). The injunction bars NeoGenomics from making, using, selling or offering for sale in the U.S. its RaDaR MRD test, barring certain exceptions, and marks Natera’s second major legal victory for Signatera in the month of December, the analyst tells investors. The firm is making no changes to revenue or earnings estimates for either Natera or NeoGenomics, but is applying a higher multiple on its 2025 revenue estimate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NTRA:
- Natera wins preliminary injunction in NeoGenomics patent infringement lawsuit
- Natera begins study on benefits of Signatera’s method for ctDNA quantification
- Natera initiated with bullish view at Guggenheim, here’s why
- Natera initiated with bullish view at Wolfe Research, here’s why
- Natera initiated with bullish view at Wolfe Research